874:HKEXGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H Analysis

Technical outlook: The stock trades at 0.055 MYR, below its 20‑day SMA (0.059), 50‑day SMA (0.059) and 200‑day SMA (0.064), indicating a bearish price bias. RSI sits at 38, below the 40 threshold, and the MACD histogram is negative with a bearish signal line, reinforcing downside momentum. Volume is increasing, but the price is hovering near the computed support of 0.055 and faces resistance around 0.07, while the 30‑day volatility is an elevated 82% and beta is modest at 0.78, suggesting high price swings with limited market correlation. The Fear‑Greed Index reads “Extreme Greed,” yet the DCF fair value (0.053) is slightly below the current price, hinting at a modest overvaluation.
Fundamental outlook: Revenue has contracted by 22.6% and margins are deep in the red (gross 20.3%, operating –13.4%, profit –25.3%). The company carries a heavy debt load (MYR 27.3 bn) with a debt‑to‑equity of 44%, negative operating cash flow, and a negative ROE of –7.2%. However, the price‑to‑book ratio is low at 0.58 and free cash flow is positive, offering a value cushion. No dividend is paid, and sustainability is weak given the cash flow profile. Overall, the blend of technical weakness and distressed fundamentals points to a cautious stance.